查看2017.HSA.doxorubicin.AC.vs.ADTIC的源代码
←
2017.HSA.doxorubicin.AC.vs.ADTIC
跳转到:
导航
,
搜索
因为以下原因,你没有权限编辑本页:
您刚才请求的操作只有这个用户组中的用户才能使用:
用户
您可以查看并复制此页面的源代码:
==='''结论 (Results)'''=== 在2008年至2014年期间,有27只狗符合纳入标准并被招募:其中18只(66.6%)接受了辅助AC(第1组),而其余9只(33.3%)接受了ADTIC治疗(第2组)。狗的特征列于表2。 Between 2008 and 2014, 27 dogs met the inclusion criteria and were enrolled: 18 (66.6%) of them received adjuvant AC (group 1), whereas the remaining 9 (33.3%) were treated with ADTIC (group 2). Features of the dogs are listed in Table 2. 入院时,两个治疗组在年龄、体重、品种、性别、肿瘤的主要位置和分期方面没有差异,而分配接受ADTIC的狗的手术切缘往往不完全,而不是接受AC的狗[分别为9例中的5例(55.6%)和18例中的2例(11.1%);P =0.024]。 At admission, the two treatment groups did not differ for age, body weight, breed, sex, primary location of the tumour and stage, whereas surgical margins were more often incomplete in dogs allocated to receive ADTIC than in those allocated to receive AC [5 of 9 (55.6%) versus 2 of 18 (11.1%), respectively; P =0.024]. 第 1 组 有九只混种犬,两只拳击手,两只德国牧羊犬,两只金毛猎犬,一只英国二传手,一只拉布拉多猎犬和一只意大利甘蔗犬。中位年龄为 9.5 岁(范围:6-13 岁),中位体重为 31 公斤(范围:5.2-46.4 公斤)。有 11 只雄性(n=3 只绝育)和 7 只雌性狗(n=4 只绝育)。15 只狗的原发部位是脾脏,其中 11 只因脾破裂而出现腹血。其余三只狗分别患有肾脏、肝脏和皮下 HSA。 根据癌症位置,每只狗都接受了手术,包括脾切除术、左肝叶切除术、肾切除术或切除皮下肿瘤。组织病理学评估显示肝脏和皮下 HSA 的手术切缘干净。 根据 TNM 分类,16 只狗被认为患有 II 期,2 只患有 III 期 HSA。两只患有III期疾病的狗都有脾脏HSA和网膜转移的宏观证据;在腹腔切开术中怀疑转移性疾病,并通过组织病理学检查证实。观察到多发性粟粒病变,无法进行转移灶切除术。没有区域淋巴腺肿大和/或其他转移部位的记录。表2总结了案例。 从手术到化疗开始的中位时间为 9 天(范围:7-10 天)。化疗周期的中位数为 4 个(范围:2-5),多柔比星的中位累积剂量为 120 mg/m^2,环磷酰胺的中位累积剂量为 1200 mg/m^2。该协议接受的 SDI 中位数与预期的 SDI 相对应,因为没有一只狗需要减少剂量和/或延迟治疗。 Group 1 There were nine mixed breed dogs, two Boxer, two German shepherd, two Golden retrievers, one English setter, one Labrador retriever and one Italian cane corso. Median age was 9.5 years (range: 6–13 years) and median weight was 31 kg (range: 5.2–46.4 kg). There were 11 males (n=3 neutered) and 7 female dogs (n=4 spayed). HSA occurred in the spleen as primary site in 15 dogs: 11 of them presented with hemoabdomen because of splenic rupture. The remaining three dogs had a renal, hepatic and a subcutaneous HSA, respectively. Each dog underwent surgery, consisting of splenectomy, left hepatic lobectomy, nephrectomy or removal of the subcutaneous tumour, according to cancer location. Histopathological evaluation revealed clean surgical margins in the hepatic and subcutaneous HSA. According to the TNM classification, 16 dogs were considered having stage II and 2 having stage III HSA. Both dogs with stage III disease had a splenic HSA and macroscopic evidence of metastasis to the omentum; metastatic disease was suspected during celiotomy, and this was confirmed through histopathological examination. Multiple miliary lesions were observed, and metastasectomy could not be performed. No regional lymphadenomegaly and/or other metastatic sites could be documented. Cases are summarized in Table 2. The median time from surgery to the initiation of chemotherapy was 9 days (range: 7–10 days). The median number of chemotherapy cycles was 4 (range: 2–5), with a median cumulative dose of doxorubicin of 120 mg m–2 and a median cumulative dose of cyclophosphamide of 1200 mg m−2. The median received SDIs for this protocol corresponded to the intended SDIs, as none of the dogs required dose reductions and/or treatment delays. 第 2 组 有六只混种犬,一只美国斯塔福德郡梗犬,一只金毛猎犬和一只拉布拉多猎犬。中位年龄为 9 岁(范围:8-14 岁),中位体重为 26.4 公斤(范围:10-39.2 公斤)。有三只雄性(n=1 绝育)和六只雌性狗(n=4 绝育)。HSA发生在5只狗的脾脏中,是主要部位;所有患者均因脾破裂而出现腹腔积血。两只狗有皮下HSA,一只狗有肾,一只有肠系膜HSA。根据TNM分类,6只狗患有II期HSA(n=2脾脏,n=2皮下,n=1肾和n=1肠系膜),3只狗患有III期HSA(n=3脾脏)。一只患有皮下 II 期 HSA 的狗患有同侧区域淋巴结淋巴腺肿大;手术切除,组织病理学证实转移性疾病。患有III期疾病的三只狗中有两只有腹膜转移,一只有肝转移。所有狗都接受了手术,包括脾切除术、肾切除术、肠系膜和皮下肿瘤切除术,具体取决于癌症位置;在所有III期疾病病例中,由于转移灶数量众多,无法进行转移灶切除术。切除两个边缘不完整的皮下 HSA。表2总结了案例。 从手术到化疗开始的中位时间为 9 天(范围:7-10 天)。化疗周期的中位数为 4 个(范围:2-4 个周期),阿霉素的中位累积剂量为 120 mg/m^2(范围:60-120 mg/m^2,达卡巴嗪的中位累积剂量为 4000 mg/m^2(范围:2000-4000 mg/m^2)。化疗周期的中位数为4个(范围:2-4)。该协议接收的 SDI 中位数与预期的 SDI 相对应。 Group 2 There were six mixed breed dogs, one American Staffordshire terrier, one Golden retriever and one Labrador retriever. Median age was 9 years (range: 8–14 years) and median weight was 26.4 kg (range: 10–39.2 kg). There were three males (n=1 neutered) and six female dogs (n=4 spayed). HSA occurred in the spleen as primary site in five dogs; all of them presented with hemoperitoneum because of splenic rupture. Two dogs had subcutaneous HSA, one dog had a renal and one had a mesenteric HSA. According to the TNM classification, six dogs had stage II HSA (n=2 splenic, n=2 subcutaneous, n=1 renal and n=1 mesenteric), and three dogs had stage III HSA (n=3 splenic). One dog with subcutaneous stage II HSA had lymphadenomegaly of the ipsilateral regional lymph node; this was surgically excised, and metastatic disease was confirmed on histopathology. Two of the three dogs with stage III disease had peritoneal metastases, and one had liver metastases. All dogs underwent surgery, consisting of splenectomy, nephrectomy, removal of mesenteric and subcutaneous tumour, according to cancer location; in all cases with stage III disease, metastasectomy was not possible because of the multiple number of metastases. Two subcutaneous HSA were removed with incomplete margins. Cases are summarized in Table 2. The median time from surgery to the initiation of chemotherapy was 9 days (range: 7–10 days). The median number of chemotherapy cycles was 4 (range: 2–4 cycles), with a median cumulative dose of doxorubicin of 120 mg m−2 (range: 60–120 mg m−2) and a median cumulative dose of dacarbazine of 4000 mg m−2 (range: 2000–4000 mg m−2). The median number of chemotherapy cycles was 4 (range: 2–4). The median received SDIs for this protocol corresponded to the intended SDIs. [[文件:2017.HSA.doxorubicin.AC.vs.ADTIC.02.png]] <br>
返回到
2017.HSA.doxorubicin.AC.vs.ADTIC
。
个人工具
登录
名字空间
页面
讨论
变换
查看
阅读
查看源代码
查看历史
操作
搜索
导航
首页
社区专页
新闻动态
最近更改
随机页面
帮助
工具箱
链入页面
相关更改
特殊页面